Correlation between Serum Levels of Cyclooxygenase II and Microsomal Prostaglandin E Synthase 1 in Iraqi Colorectal Cancer Patients and Healthy Controls
DOI:
https://doi.org/10.59796/jcst.V15N4.2025.142Keywords:
serum biomarkers, COX-2, mPGES-1, CRC, ELISAAbstract
Colorectal cancer (CRC) ranks among the most widespread cancers worldwide, exhibiting considerable mortality rates. Chronic inflammation plays a crucial role in driving tumor development. Cyclooxygenase-II is an inducible enzyme that aids in the production of prostaglandins using arachidonic acid, particularly during inflammatory responses. Microsomal prostaglandin E synthase-1, functioning downstream of COX-2, specifically converts PGH2 to PGE2, and correlates with unfavorable outcomes in CRC. While their roles have been well documented in tissue, limited research has assessed their levels in serum. The present study aimed to evaluate the serum levels of COX-2 and mPGES-1 in CRC patients compared to healthy controls, and to investigate the correlation between these biomarkers across all participants, regardless of clinical grouping. A total of 70 patients, 35 newly diagnosed and 35 undergoing treatments were included, along with 30 healthy individuals as controls. Blood samples were collected from healthy individuals and Iraqi CRC patients. Serum concentrations of COX-2 and mPGES-1 were measured using ELISA. Marked variations in the levels of these enzymes were noted among the examined groups, with newly diagnosed patients showing the highest levels compared to treated patients and healthy control. A robust positive correlation was observed between levels of COX-2 and mPGES-1 in all groups. These outcomes suggest that serum levels of Cyclooxygenase II and Microsomal Prostaglandin E synthase 1 could serve as prospective diagnostic indicators for CRC patients.
References
Albasri, A. M., Elkablawy, M. A., Hussainy, A. S., Yousif, H. M., & Alhujaily, A. S. (2018). Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients: An experience from Western Saudi Arabia. Saudi Medical Journal, 39(8), 773-780. https://doi.org/10.15537/smj.2018.8.22837
Al-Saigh, T., Al-Bayati, S., Abdulmawjood, S., & Ahmed, F. (2019). Descriptive study of colorectal cancer in Iraq, 1999-2016. Annals of the College of Medicine Mosul, 41(1), 81–85.
Alwan, N. A., Lami, F., Al Nsoor, M., & Kerr, D. (2022). Trends in the incidence and mortality of the most common cancers in Iraq (Iraqi cancer registry 1999-2019). The Gulf Journal of Oncology, 1(40), 47-57.
Baidoun, F., Elshiwy, K., Elkeraie, Y., Merjaneh, Z., Khoudari, G., Sarmini, M. T., ... & Saad, A. (2021). Colorectal cancer epidemiology: recent trends and impact on outcomes. Current Drug Targets, 22(9), 998-1009. https://doi.org/10.2174/1389450121999201117115717
Cao, H., Wang, Q., Gao, Z., Xu, X., Lu, Q., & Wu, Y. (2019). Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in the diagnosis and prognostic evaluation of colorectal cancer. Cancer Cell International, 19(1), Article 163. https://doi.org/10.1186/s12935-019-0881-3
Choosang, K., Boonsilp, S., Kritsiriwuthinan, K., Chumchuang, P., Thanacharoensakun, N., Saai, A., & Pongparit, S. (2024). A dot-blot ELISA preliminary evaluation using PvMSP1-42 recombinant protein as antigen for serological diagnosis of Plasmodium vivax infection in Thailand. European Journal of Microbiology and Immunology, 14(2), 202-209. https://doi.org/10.1556/1886.2024.00008
Chun, K. S., Kim, E. H., Kim, D. H., Song, N. Y., Kim, W., Na, H. K., & Surh, Y. J. (2024). Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update. Biochemical Pharmacology, 228, Article 116259. https://doi.org/10.1016/j.bcp.2024.116259
Davies, N. M., Good, R. L., Roupe, K. A., & Yáñez, J. A. (2004). Cyclooxygenase-3: Axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3. Journal of Pharmacy & Pharmaceutical Sciences, 7(2), 217-226.
Ekhlas, S. F., Hameed, S. H. O., & Hameed, F. R. (2022). Evaluation of circulating microRNA-221 and IL-10 levels as potential diagnostic markers for colorectal cancer in correlation with prognosis. International Journal of Drug Delivery Technology, 12(3), 129–137. https://doi.org/10.25258/ijddt.12.3.23
Faki, Y., & Er, A. (2021). Different chemical structures and physiological/pathological roles of cyclooxygenases. Rambam Maimonides Medical Journal, 12(1), Article e0003. https://doi.org/10.5041/RMMJ.10426
Falih, E. S., Obaid, S. H., & Hameed, F. R. (2020). Evaluation of the role of miRNA-21 levels as a potential diagnostic biomarker for colorectal cancer associated with prognosis. Medico-legal Update, 20(2), Article 509.
Finetti, F., Paradisi, L., Bernardi, C., Pannini, M., & Trabalzini, L. (2023). Cooperation between prostaglandin E2 and epidermal growth factor receptor in cancer progression: A dual target for cancer therapy. Cancers, 15(8), Article 2374. https://doi.org/10.3390/cancers15082374
Fitzpatrick, F. A. (2004). Cyclooxygenase enzymes: regulation and function. Current Pharmaceutical Design, 10(6), 577-588. https://doi.org/10.2174/1381612043453144
Geng, S., Zhan, H., Cao, L., Geng, L., & Ren, X. (2023). Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil. Biochemistry and Cell Biology, 101(6), 501-512. https://doi.org/10.1139/bcb-2023-0101
Gretschel, J., El Hage, R., Wang, R., Chen, Y., Pietzner, A., Loew, A., ... & Schmöcker, C. (2024). Harnessing oxylipins and inflammation modulation for prevention and treatment of colorectal cancer. International Journal of Molecular Sciences, 25(10), Article 5408. https://doi.org/10.3390/ijms25105408
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883-899. https://doi.org/10.1016/j.cell.2010.01.025
Gudis, K., Tatsuguchi, A., Wada, K., Futagami, S., Nagata, K., Hiratsuka, T., ... & Sakamoto, C. (2005). Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. Laboratory Investigation, 85(2), 225-236. https://doi.org/10.1038/labinvest.3700200
Han, X., Li, H., Su, L., Zhu, W., Xu, W., Li, K., ... & Liu, H. (2014). Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase 2 in patients with gastric cancer. Biomedical Reports, 2(2), 183-187. https://doi.org/10.3892/br.2013.209
Hamada, T., Nowak, J. A., Masugi, Y., Drew, D. A., Song, M., Cao, Y.,... & Ogino, S. (2019). Smoking and risk of colorectal cancer sub-classified by tumor-infiltrating T cells. Journal of the National Cancer Institute, 111(1), 42–51. https://doi.org/10.1093/jnci/djy059
Hyodo, T., Ito, Y., Hosono, K., Uematsu, S., Akira, S., Majima, M., Takeda, A., & Amano, H. (2022). The role of mPGES-1 in promoting granulation tissue angiogenesis through regulatory T-cell accumulation. In Vivo, 36(5), 2061–2073. https://doi.org/10.21873/invivo.12932
Ibrahem, S., Ahmed, H., & Zangana, S. (2022). Trends in colorectal cancer in Iraq over two decades: Incidence, mortality, topography and morphology. Annals of Saudi Medicine, 42(4), 252-261. https://doi.org/10.5144/0256-4947.2022.252
Iraqi Cancer Registry. (2023). Ministry of Health (Iraq). Global Health Data Exchange. https://ghdx.healthdata.org/organizations/ministry-health-iraq
Kamei, D., Murakami, M., Sasaki, Y., Nakatani, Y., Majima, M., Ishikawa, Y., ... & Kudo, I. (2010). Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochemical Journal, 425(2), 361-371. https://doi.org/10.1042/BJ20090045
Karpisheh, V., Nikkhoo, A., Hojjat-Farsangi, M., Namdar, A., Azizi, G., Ghalamfarsa, G., ... & Jadidi-Niaragh, F. (2019). Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins & Other Lipid Mediators, 144, Article 106338. https://doi.org/10.1016/j.prostaglandins.2019.106338
Keivanlou, M. H., Amini-Salehi, E., Hassanipour, S., Mahapatro, A., Raghuma, N., Joukar, F., ... & Mansour-Ghanaei, F. (2023). Association between smoking and colorectal cancer in Eastern Mediterranean Regional Office (EMRO): A systematic review and meta-analysis. Saudi Journal of Gastroenterology, 29(4), 204-211. https://doi.org/10.4103/sjg.sjg_163_23
Kim, Y. H., & Kim, K. J. (2021). Upregulation of prostaglandin E2 by inducible microsomal prostaglandin E synthase-1 in colon cancer. Annals of Coloproctology, 38(2), 153-159. https://doi.org/10.3393/ac.2021.00374.0053
Kojima, F., Hioki, Y., Sekiya, H., Kashiwagi, H., Iizuka, Y., Eto, K., ... & Ichikawa, T. (2024). Microsomal prostaglandin E synthase-1 controls colonic prostaglandin E2 production and exerts a protective effect on colitis induced by trinitrobenzene sulfonic acid in mice. International Journal of Molecular Sciences, 25(22), Article 12326. https://doi.org/10.3390/ijms252212326
Korotkova, M., & Jakobsson, P. J. (2014). Characterization of microsomal prostaglandin E synthase 1 inhibitors. Basic & Clinical Pharmacology & Toxicology, 114(1), 64-69. https://doi.org/10.1111/bcpt.12162
Lin, P. C., Lin, Y. J., Lee, C. T., Liu, H. S., & Lee, J. C. (2013). Cyclooxygenase 2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients. Oncology Letters, 6(3), 733-739. https://doi.org/10.3892/ol.2013.1426
Masae, M., Nasawat, A., Sangsakul, N., Mansoh, N., & Ruanglertboon, W. (2025). Exploring the clinical characteristics and survival outcomes in colorectal cancer patients in Hatyai hospital: A retrospective cohort study. Journal of Current Science and Technology, 15(3), Article 123. https://doi.org/10.59796/jcst.V15N3.2025.123
Muthukumaradoss, K., Babu, S., Vellapandian, C., Vellapandian, C., & Palaniappan, S. (2022). The biology and chemistry of microsomal prostaglandin E synthase (mPGES)-I inhibitors for cancer biomedicine. In Systems Biomedicine Approaches in Cancer Research. Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-19-1953-4_4
Mohammed, A., & Shoemaker, R. H. (2022). Targeting the leukotriene pathway for colon cancer interception. Cancer Prevention Research, 15(10), 637-640. https://doi.org/10.1158/1940-6207.CAPR-22-0331
Murakami, M., & Kudo, I. (2006). Prostaglandin E synthase: A novel drug target for inflammation and cancer. Current Pharmaceutical Design, 12(8), 943-954. https://doi.org/10.2174/138161206776055912
Mowat, A. N., & Al-Abady, Z. N. (2025). Study the Impact of NADPH oxidase1, TNF-alpha and Cyclooxygenase-2 On Colon Cancer Patients. Asian Pacific Journal of Cancer Prevention: APJCP, 26(3), 877-887. https://doi.org/10.31557/APJCP.2025.26.3.877
Myung, S. J., Rerko, R. M., Yan, M., Platzer, P., Guda, K., Lawrence, E.,... & Markowitz, S. D. (2006). 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 103(32), 12098–12102. https://doi.org/10.1073/pnas.0603235103
Nanda, N., & Dhawan, D. K. (2021). Role of cyclooxygenase-2 in colorectal cancer. Frontiers in Bioscience-landmark, 26(4), 706-716. https://www.imrpress.com/journal/fbl/26/4/10.2741/4914
Negi, R. R., Rana, S. V., Gupta, V., Gupta, R., Chadha, V. D., Prasad, K. K., & Dhawan, D. K. (2019). Over-expression of cyclooxygenase-2 in colorectal cancer patients. Asian Pacific Journal of Cancer Prevention: APJCP, 20(6), 1675-1681. https://doi.org/10.31557/APJCP.2019.20.6.1675
Purnama, A., Lukman, K., Rudiman, R., Prasetyo, D., Fuadah, Y., Nugraha, P., & Candrawinata, V. S. (2023). The prognostic value of COX-2 in predicting metastasis of patients with colorectal cancer: A systematic review and meta analysis. Heliyon, 9(10), Article e21051. https://doi.org/10.1016/j.heliyon.2023.e21051
Radhi, A. A., Muslim, O. T., & Abdlmaged, M. A. (2018). Epidemiological distribution of colorectal cancer in AL-Diwaniyah province, Iraq: An observational study. Journal of Pharmaceutical Sciences and Research, 10(7), 1758-1760.
Rahman, M., Selvarajan, K., Hasan, M. R., Chan, A. P., Jin, C., Kim, J., ... & Tai, I. T. (2012). Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia, 14(7), 624-633. https://doi.org/10.1593/neo.12486
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 986-1000. https://doi.org/10.1161/ATVBAHA.110.207449
Roelofs, H. M., Te Morsche, R. H., van Heumen, B. W., Nagengast, F. M., & Peters, W. H. (2014). Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterology, 14(1), Article 9005. https://doi.org/10.1186/1471-230X-14-1
Sabah, Y. H., & Hassan, F. (2024). Comparison of serum vitamins C, D, and E in Iraqi colorectal cancer patients with and without non-alcoholic fatty liver disease to healthy individuals. Journal of Current Science and Technology, 14(3), Article 56. https://doi.org/10.59796/jcst.V14N3.2024.56
Sasaki, Y., Nakatani, Y., & Hara, S. (2015). Role of microsomal prostaglandin E synthase-1 (mPGES-1)-derived prostaglandin E2 in colon carcinogenesis. Prostaglandins & Other Lipid Mediators, 121, 42-45. https://doi.org/10.1016/j.prostaglandins.2015.06.006
Seo, T., Tatsuguchi, A., Shinji, S., Yonezawa, M., Mitsui, K., Tanaka, S., ... & Sakamoto, C. (2009). Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Archiv, 454(6), 667-676. https://doi.org/10.1007/s00428-009-0777-z
Serrano-López, J., & Martín-Antonio, B. (2021). Inflammaging, an imbalanced immune response that needs to be restored for cancer prevention and treatment in the elderly. Cells, 10(10), Article 2562. https://doi.org/10.3390/cells10102562
Shalaby, S. M., Shawky, S. A., Ashour, H., & Sarhan, W. (2025). The interplay between COX-2, chemotherapeutic drugs, and chemoresistance in colon cancer. Scientific Reports, 15(1), Article 15837. https://doi.org/10.1038/s41598-025-98451-9
Shaukat, A., Kahi, C. J., Burke, C. A., Rabeneck, L., Sauer, B. G., & Rex, D. K. (2021). ACG clinical guidelines: Colorectal cancer screening 2021. The American Journal of Gastroenterology, 116(3), 458-479. https://doi.org/10.14309/ajg.0000000000001122
Sheng, J., Sun, H., Yu, F. B., Li, B., Zhang, Y., & Zhu, Y. T. (2020). The role of cyclooxygenase-2 in colorectal cancer. International Journal of Medical Sciences, 17(8), Article 1095. https://doi.org/10.7150/ijms.44439
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., ... & Jemal, A. (2020). Colorectal cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(3), 145-164. https://doi.org/10.3322/caac.21601
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023). Colorectal cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(3), 233-254. https://doi.org/10.3322/caac.21772
Sophonnithiprasert, T., Konjanthet, S., Narinnork, N., Prompat, N., Benjakul, S., Saetang, J., ... & Rattanaburee, T. (2025). B-AP15 inhibited colon cancer cell proliferation by decreasing CDK6, Cyclin A, Cyclin E, c-Myc, and VEGF gene expression. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-16. https://doi.org/10.1007/s00210-025-03940-3
Stamatakis, K., Jimenez-Martinez, M., Jimenez-Segovia, A., Chico-Calero, I., Conde, E., Galán-Martínez, J., ... & Fresno, M. (2015). Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression. Oncotarget, 6(37), 39941–39959. https://doi.org/10.18632/oncotarget.5402
Szweda, M., Rychlik, A., Babińska, I., & Pomianowski, A. (2019). The significance of cyclooxygenase-2 in oncogenesis: Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology. Journal of Veterinary Research, 63(2), 215–224. https://doi.org/10.2478/jvetres-2019-0030
Yang, W., Luo, Y., Hu, S., Li, Y., & Liu, Q. (2018). Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer. Oncology Letters, 16(2), 1551-1556. https://doi.org/10.3892/ol.2018.8792
Yarla, N. S., Madka, V., Pathuri, G., & Rao, C. V. (2020). Molecular targets in precision chemoprevention of colorectal cancer: An update from pre-clinical to clinical trials. International Journal of Molecular Sciences, 21(24), Article 9609. https://doi.org/10.3390/ijms21249609
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Journal of Current Science and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
